As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a ...
According to Boehringer, Hernexeos achieved a 77% objective response rate (OOR) in a cohort of previously untreated HER2+ NSCLC patients in Beamion Lung-1, with 8% complete responses and 69% partial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback